Osteoporosis secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Secondary prevention involves the use of pharmacologic therapy as an intervention as soon as osteoporosis is recognized.  Primary prevention measures should also be used with pharmacologic therapy.  The agent chosen for therapy is based on what would work best for the individual patient.
Effective measures for the [[secondary prevention]] of [[osteoporosis]] include [[pharmacological]] therapy and also life style modification as soon as [[osteoporosis]] is diagnosed.


==Secondary Prevention==
==Secondary prevention==
===Pharmacologic Therapy===
Effective measures for the [[secondary prevention]] of [[osteoporosis]] include [[pharmacological]] therapy and also life style modification.
 
===Pharmacological therapy===
   
   
* All patients who are receiving pharmacologic treatment for osteoporosis, should also undergo lifestyle modifications and supplementation to also prevent further bone loss.
* The primary most important goal for treatment of [[osteoporosis]] is to reduce longtime [[fracture]] risk in patients. Increasing [[Bone mineral density|bone mineral density (BMD)]] in response to the treatment is far less important than improvement of clinical aspects of [[osteoporosis]], i.e., [[Osteoporosis|osteoporotic]] [[Bone fracture|fracture]]. Therefore, most of the [[drugs]]' efficacy are measured by the extend they improve the [[fracture]] risk, in turn of increasing [[Bone mineral density|BMD]].<sup>[[Osteoporosis medical therapy#cite note-pmid11893367-3|[3]]]</sup>
* [[Bisphosphonates]] - these are potent agents which inhibit resorption of bone<ref name="pmid22805729">{{cite journal |author=Zhang J, Wang R, Zhao YL, ''et al.'' |title=Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis |journal=Asian Pac J Trop Med |volume=5 |issue=9 |pages=743–8 |year=2012 |month=September |pmid=22805729 |doi=10.1016/S1995-7645(12)60118-7 |url=}}</ref>.  In turn they increase bone mineral density and decrease the risk of fractures.  They include drugs called alendronate, risendronate, ibandronate, and zoledronic acid.
* It has to explain for patients that treatment purpose is to reduce their [[fracture]] risk in the future. During the treatment, if a single [[fracture]] happened, it is not necessarily reflect of treatment failure; despite the major complicates [[fractures]] that may need to start alternative treatments or patient referral to [[specialist]].<sup>[[Osteoporosis medical therapy#cite note-pmid28761958-4|[4]]]</sup>
* Selective Estrogen Receptor Modulators - otherwise known as SERM's, are approved for the prevention of post-menopausal osteoporosis. They have been shown to increase bone mineral density and decrease the risk of vertebral fractures. Raloxifene <ref name="pmid22405286">{{cite journal |author=Dadiboyena S |title=Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator |journal=Eur J Med Chem |volume=51 |issue= |pages=17–34 |year=2012 |month=May |pmid=22405286 |doi=10.1016/j.ejmech.2012.02.021 |url=}}</ref> is the only SERM approved for use in the United States.
* [[Calcium]] and [[vitamin D]] supplementation have been found to be effective in reducing the long term [[Bone fracture|fracture]] risk, significantly. In order to suggest the people to use [[vitamin D]] and [[calcium]] [[supplements]], first the [[physician]] has to become sure that patient is not able to obtain the [[nutrients]] through daily intake. The available supplemental ions of [[calcium]] include [[calcium carbonate]] and [[calcium citrate]]; and [[vitamin D3]] has various [[Dosage form|dosage forms]].<sup>[[Osteoporosis medical therapy#cite note-pmid24131178-5|[5]]]</sup>
* [[Estrogen]] - with or without medroxyprogesterone can be used to prevent osteoporosis, however in general the risks outweigh the benefits, so it is not used as a first-line therapy. It is used in women who have a significant risk of osteoporotic fractures and cannot take non-estrogen medications.
 
=== Life style modifications ===
* [[Exercise]]: Exercise promotes the [[mineralization]] of [[bone]], and [[bone]] accumulation particularly during growth. High impact exercise in particular has been shown to prevent the development of [[osteoporosis]], however it can have a negative effect on bone [[mineralization]] in cases of poor [[nutrition]], such as [[anorexia nervosa]] and [[celiac disease]].
* [[Nutrition]]: A [[diet]] high in [[calcium]] and [[vitamin D]] prevents [[bone loss]]. Patients at risk for [[osteoporosis]], such as persons with chronic [[steroid]] use are generally treated with [[vitamin D]] and [[calcium]] supplementation. In [[Kidney|renal]] disease, more active forms of [[vitamin D]], such as 1,25-dihydroxycholecalciferol or [[calcitriol]] are used; as the kidney can not adequately generate [[calcitriol]] from [[calcidiol]] (25-hydroxycholecalciferol), which is the storage form of [[vitamin D]].
* Quitting [[smoking]] helps prevent [[osteoporosis]], as well as other diseases.
* Not drinking alcohol, or drinking only in moderation (1–2 alcoholic beverages/day)
* Taking certain medications linked to [[osteoporosis]] ([[anticonvulsants]] or [[corticosteroids]]) only at the least possible dose and time needed.<sup>[[Osteoporosis life style modification#cite note-BuckleyGuyatt2017-1|[1]]]</sup>


==References==
==References==

Revision as of 03:29, 16 August 2017

Osteoporosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Osteoporosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Life Style Modification
Pharmacotherapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Osteoporosis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Osteoporosis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Osteoporosis secondary prevention

CDC on Osteoporosis secondary prevention

Osteoporosis secondary prevention in the news

Blogs on Osteoporosis secondary prevention

Directions to Hospitals Treating Osteoporosis

Risk calculators and risk factors for Osteoporosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Raviteja Guddeti, M.B.B.S. [3]; Charmaine Patel, M.D. [4]

Overview

Effective measures for the secondary prevention of osteoporosis include pharmacological therapy and also life style modification as soon as osteoporosis is diagnosed.

Secondary prevention

Effective measures for the secondary prevention of osteoporosis include pharmacological therapy and also life style modification.

Pharmacological therapy

Life style modifications

References

Template:WS Template:WH